Dosimetry of Organs at Risk for Lutathera Treatment Between Meningioma and Neuroendocrine Tumor (LUDOMET)
To Compare the Dosimetry of Organs at Risk in Patients Treated With Lutathera® for Meningioma Versus Neuroendocrine Tumor (NET).
Tumor dosimetry for meningiomas is substantially lower (7 to 8 times lower) than for neuroendocrine tumors (NETs), even though the injected activities are identical for both indications.
The hypothesis of this study is that organs at risk receive a higher absorbed dose in the case of meningiomas than with NETs.
A literature review has supported this hypothesis; therefore, it is appropriate to verify it through this retrospective study.
研究概览
地位
条件
详细说明
Tumor dosimetry for meningiomas is substantially lower (7 to 8 times lower) than for neuroendocrine tumors (NETs), even though the injected activities are identical for both indications.
The hypothesis of this study is that organs at risk receive a higher absorbed dose in the case of meningiomas than with NETs.
A literature review has supported this hypothesis; therefore, it is appropriate to verify it through this retrospective study.Thus, the aim of the study will be to determine the dosimetry of organs at risk in patients treated with Lutathera® for meningioma and for a neuroendocrine tumor (NET).
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Antoine VERGER, MD,PhD
- 电话号码:+33 0383155567
- 邮箱:a.verger@chru-nancy.fr
研究联系人备份
- 姓名:Véronique Roch, MSc
- 电话号码:0383154276
- 邮箱:v.roch@chru-nancy.fr
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
SPECT scans recorded for each patient who received at least one cycle of Lutathera® treatment for a meningioma or a NET will be analyzed.
描述
Inclusion Criteria:
- Patients who have received at least one course of Lutathera® treatment for a meningioma or a NET
Exclusion Criteria:
- Patient who has objected to the collection of their data
学习计划
研究是如何设计的?
设计细节
- 观测模型:OTHER
- 时间观点:RETROSPECTIVE
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
To compare the dosimetry of organs at risk in patients treated with Lutathera® for meningioma versus neuroendocrine tumor
大体时间:Day 1
|
Calculation of dosimetry for organs at risk (kidney, spleen, liver, bone marrow) in the two patient populations treated with Lutathera® |
Day 1
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
To evaluate the safety monitoring of Lutathera® treatment in both populations at 3 months after the last Lutathera® cycle
大体时间:3 months
|
Biology results |
3 months
|
|
To evaluate the safety monitoring of Lutathera® treatment in both populations at 3 12 months after the last Lutathera® cycle
大体时间:12 months
|
Biology results |
12 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.